Global GIDEON data: Subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma

Masatoshi Kudo; Sheng‐Long Ye; Keiko Nakajima; Riccardo Lencioni

doi:10.1093/annonc/mdw521.067

Related publications

Article2016

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON

Jean-François H. Geschwind, Masatoshi Kudo, Jorge A. Marrero, Alan P. Venook, Xiao-Ping Chen, Jean-Pierre Bronowicki, Lucy Dagher, Junji Furuse, Laura Ladrón de Guevara, Christos N. Papandreou, Arun J. Sanyal, Tadatoshi Takayama, Sheng-Long Ye, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Riccardo Lencioni

Article2016

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON

Masatoshi Kudo, Masafumi Ikeda, Tadatoshi Takayama, Kazushi Numata, Namiki Izumi, Junji Furuse, Takuji Okusaka, Masumi Kadoya, Satoshi Yamashita, Yuichiro Ito, Norihiro Kokudo

Article2016

Regional differences in sorafenib‐treated patients with hepatocellular carcinoma: <scp>GIDEON</scp> observational study

Masatoshi Kudo, Riccardo Lencioni, Jorge A. Marrero, Alan P. Venook, J.-P. Bronowicki, Xiaoping Chen, Lucy Dagher, Junji Furuse, Jean‐François H. Geschwind, Laura Ladrón de Guevara, Christos N. Papandreou, Arun J. Sanyal, Tadatoshi Takayama, Seung Kew Yoon, Keiko Nakajima, Robert Lehr, Stephanie Heldner, Sheng‐Long Ye

Article2019

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

Masahiro Kobayashi, Masatoshi Kudo, Namiki Izumi, Shuichi Kaneko, Mie Azuma, Ronda Copher, Genevieve Meier, Janice Pan, Mika Ishii, Shunya Ikeda

Article2023

Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.

Richard S. Finn, Philippe Merle, Masafumi Ikeda, Heinz‐Josef Klümpen, Gianluca Masi, Alessandro Granito, Ho Yeong Lim, Masatoshi Kudo, Shukui Qin, René Gerolami, Yi‐Hsiang Huang, Do Young Kim, Matthias Pinter, Naoya Kato, Masayuki Kurosaki, Kazushi Numata, Javeed Khan, Kirhan Özgürdal, Yoon Jun Kim

Global GIDEON data: Subgroup analysis of sorafenib dosing pattern in patients with unresectable hepatocellular carcinoma

Discussion(0)

Related publications

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON

Regional differences in sorafenib‐treated patients with hepatocellular carcinoma: <scp>GIDEON</scp> observational study

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.